| Ytd | -85.95% | |
| 1y | -76.52% |
| Open | 5.87 | Prev Close | 5.87 | Low | 5.75 | High | 5.89 | Mkt Cap | 260.97M |
| Vol | 94.74K | Avg Vol | 1.80M | EPS | -2.15 | P/E | N/A | Forward P/E | -18.18 |
| Beta | 1.33 | Short Ratio | 10.62 | Inst. Own | 100.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 33.12 | 200-d Avg | 37.90 | 1yr Est | 53.20 |
SION News
SAN DIEGO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating poten
SAN DIEGO, Aug. 27, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potentia
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
LOS ANGELES, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
SAN DIEGO, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigatin
LOS ANGELES, Aug. 25, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its invest
BENSALEM, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its invest
Gainers BioVie (NASDAQ:BIVI) shares increased by 39.4% to $1.77 during Wednesday's regular sess
Wedbush analyst Laura Chico downgrades Sionna Therapeutics (NASDAQ:SION) from Outperform to Neutr
Sionna Therapeutics topline clinical data for cystic fibrosis programs disappoints, opting to discon
Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regul
US stocks mixed, Dow Jones down 0.2% midday. Energy shares up 3%, real estate down 1.4%. National En
Dow Jones fell 0.2% as US stocks opened lower. Energy shares rose 1.9%, while real estate stocks dro
Gainers Jin Medical International (NASDAQ:ZJYL) stock rose 70.7% to $3.67 during Monday's pre-m
Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to
Guggenheim analyst Yatin Suneja maintains Sionna Therapeutics (NASDAQ:SION) with a Buy and raises
Sionna Therapeutics (NASDAQ:SION) reported quarterly losses of $(0.66) per share which missed the an
Citizens analyst Jonathan Wolleben reiterates Sionna Therapeutics (NASDAQ:SION) with a Market Out
Stifel analyst Paul Matteis maintains Sionna Therapeutics (NASDAQ:SION) with a Buy and raises the
BTIG analyst Kambiz Yazdi reiterates Sionna Therapeutics (NASDAQ:SION) with a Buy and maintains $
Sionna Therapeutics (NASDAQ:SION) reported quarterly losses of $(0.60) per share which missed the an
Top Wall Street analysts changed outlook on top names. Check analyst ratings page for full changes.
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Cit
Wedbush analyst Laura Chico initiates coverage on Sionna Therapeutics (NASDAQ:SION) with a Outper
Jones Trading analyst Debanjana Chatterjee maintains Sionna Therapeutics (NASDAQ:SION) with a Buy
BTIG analyst Kambiz Yazdi reiterates Sionna Therapeutics (NASDAQ:SION) with a Buy and maintains $
Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to
Guggenheim analyst Yatin Suneja maintains Sionna Therapeutics (NASDAQ:SION) with a Buy and raises
BTIG analyst Kambiz Yazdi reiterates Sionna Therapeutics (NASDAQ:SION) with a Buy and maintains $
Citizens analyst Jonathan Wolleben initiates coverage on Sionna Therapeutics (NASDAQ:SION) with a
BTIG analyst Kambiz Yazdi reiterates Sionna Therapeutics (NASDAQ:SION) with a Buy and maintains $
BTIG analyst Kambiz Yazdi maintains Sionna Therapeutics (NASDAQ:SION) with a Buy and raises the p
LifeSci Capital analyst Cory Jubinville initiates coverage on Sionna Therapeutics (NASDAQ:SION) w
RBC Capital analyst Brian Abrahams downgrades Sionna Therapeutics (NASDAQ:SION) from Sector Perfo
BTIG analyst Kambiz Yazdi initiates coverage on Sionna Therapeutics (NASDAQ:SION) with a Buy rati
Sionna Therapeutics (NASDAQ:SION) reported quarterly losses of $(0.46) per share which beat the anal
Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were gener
SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosisTopline d
Freedom Capital Markets analyst Ilya Zubkov initiates coverage on Sionna Therapeutics (NASDAQ:SIO
Jones Trading analyst Debanjana Chatterjee initiates coverage on Sionna Therapeutics (NASDAQ:SION
Raymond James analyst Chris Raymond initiates coverage on Sionna Therapeutics (NASDAQ:SION) with
RBC Capital analyst Brian Abrahams initiates coverage on Sionna Therapeutics (NASDAQ:SION) with a
Sionna Therapeutics (NASDAQ:SION) reported quarterly losses of $(0.41) per share which beat the anal